NEWS
FDA grants binx health CLIA-Waiver for its first-of-kind binx io platform for chlamydia and gonorrhea testing
Financing led by OrbiMed, and includes Arrowmark Partners, Hildred Capital Management, Alta Life Sciences and Parian Global
Proceeds to support expansion of manufacturing for first-of-kind, FDA-cleared, CLIA-waived binx io rapid molecular diagnostic test, menu expansion, and the company’s data and software architecture for its at-home and in-clinic businesses
Platform poised to be first CLIA-waived CRISPR-based, point-of-care COVID-19 device with central-lab performance, developed in collaboration with Sherlock Biosciences
By improving access to convenient, efficient STI testing, binx health aims to help reduce STI transmission and deliver consumer-centric care
FDA NEWS RELEASE
First ever 30-minute, CLIA-waived, molecular PCR Test for CT/NG now available for OBGYN, physician offices and retail settings holding certificates of waiver
binx health, a population health technology company that provides convenient healthcare solutions, announced today that its FDA emergency-use authorized at-home nasal swab COVID-19 Sample Collection Kit is now available for…
Former LabCorp Chairman and CEO joins binx board during period of rapid growth
binx molecular point-of-care platform poised to transform care for chlamydia and gonorrhea, the two most tested for sexually-transmitted infections
